NCT04884035 2026-04-17
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Celgene
Phase 1 Recruiting
Clinical Trials
12 trialsNCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06925737 2026-04-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT06890884 2026-04-02
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07005154 2026-04-02
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT04300556 2026-03-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT06091254 2026-03-11
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06952803 2026-03-10
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT06911502 2025-12-05
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting